| 崔宏福,邰 春,王 谦,张 杰,叶详东.肺力咳胶囊联合布地奈德福莫特罗粉吸入剂对慢性阻塞性肺疾病急性加重期患者血气分析指标和MMP-9/TIMP-1失衡的影响[J].,2023,(18):3568-3571 |
| 肺力咳胶囊联合布地奈德福莫特罗粉吸入剂对慢性阻塞性肺疾病急性加重期患者血气分析指标和MMP-9/TIMP-1失衡的影响 |
| Effect of Feilike Capsule Combined with Budesonide and Formoterol Powder Inhalation on Blood Gas Analysis Indexes and MMP-9/TIMP-1 Imbalance in Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease |
| 投稿时间：2023-03-03 修订日期：2023-03-26 |
| DOI：10.13241/j.cnki.pmb.2023.18.033 |
| 中文关键词: 肺力咳胶囊 布地奈德福莫特罗粉吸入剂 慢性阻塞性肺疾病 急性加重期 血气分析指标 基质金属蛋白酶-9 金属蛋白酶抑制物-1 |
| 英文关键词: Feilike capsule Budesonide and fomotrol powder inhalation Chronic obstructive pulmonary disease Acute exacerbation Blood gas analysis indexes Matrix metalloproteinase-9 Tissue inhibitor of metalloproteinase-1 |
| 基金项目:安徽省第六批卫生健康适宜技术推广项目（SYJS202130） |
|
| 摘要点击次数: 476 |
| 全文下载次数: 352 |
| 中文摘要: |
| 摘要 目的：探讨肺力咳胶囊联合布地奈德福莫特罗粉吸入剂对慢性阻塞性肺疾病急性加重期（AECOPD）患者血气分析指标和基质金属蛋白酶-9（MMP-9）/金属蛋白酶抑制物-1（TIMP-1）失衡的影响。方法：选取皖南医学院附属铜陵市人民医院2019年4月~2022年7月期间收治的AECOPD患者81例。按照随机数字表法，将患者分为对照组（40例，接受布地奈德福莫特罗粉吸入剂治疗）和研究组（41例，接受肺力咳胶囊联合布地奈德福莫特罗粉吸入剂治疗）。对比两组临床症状改善情况、肺功能指标、MMP-9/TIMP-1相关指标、血气分析指标，观察两组不良反应发生率。结果：研究组的临床症状缓解时间均短于对照组（P<0.05）。治疗14 d后，两组第1秒用力呼气容积（FEV1）、用力肺活量（FVC）、FEV1/FVC升高，且研究组较对照组更高（P<0.05）。治疗14 d后，两组血氧饱和度（SpO2）、血氧分压（PO2）升高，血二氧化碳分压（PCO2）下降，且研究组变化较对照组幅度更大（P<0.05）。治疗14 d后，两组血清MMP-9、TIMP-1水平及MMP-9/TIMP-1均下降，且研究组较对照组更低（P<0.05）。两组不良反应发生率对比无差异（P>0.05）。结论：布地奈德福莫特罗粉吸入剂联合肺力咳胶囊治疗对AECOPD患者，有助于临床症状的缓解，改善肺功能和血气分析指标，调节MMP-9/TIMP-1失衡。 |
| 英文摘要: |
| ABSTRACT Objective: To explore the effect of Feilike capsule combined with budesonide and formoterol powder inhalation on blood gas analysis indexes and matrix metalloproteinase-9 (MMP-9)/tissue inhibitor of metalloproteinase-1 (TIMP-1) imbalance in patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD). Methods: 81 patients with AECOPD who were admitted to Tongling People's Hospital affiliated with Wannan Medical College from April 2019 to July 2022 were selected. According to the method of random number table, the patients were divided into control group (40 cases, treated with budesonide and formoterol powder inhalation) and study group (41 cases, treated with Feilike capsule combined with budesonide and formoterol powder inhalation). The Clinical symptom improvement, lung function indicators, MMP-9/TIMP-1 related indicators, blood gas analysis indicators were compared between the two groups, and the incidence of adverse reactions between the two groups were observed. Results: The clinical symptom relief time of the study group was shorter than that of the control group (P<0.05). 14 d after treatment, the forced expiratory volume in the first second (FEV1), forced vital capacity (FVC), FEV1/FVC increased in the two groups, and the study group was higher than those in the control group (P<0.05). 14 d after treatment, the oxygen saturation (SpO2), partial pressure of oxygen (PO2) increased and partial pressure of carbon dioxide (PCO2) decreased in the two groups, and the study group showed greater changes than those in the control group (P<0.05). 14 d after treatment, the levels of serum MMP-9, TIMP-1, and MMP-9/TIMP-1 decreased in the two groups, and the study group were lower than those in the control group (P<0.05). There was no statistically significant difference in the incidence of adverse reactions between the two groups (P>0.05). Conclusion: Budesonide and formoterol powder inhalation combined with Feilike capsule in the treatment of patients with AECOPD can help alleviate clinical symptoms, improve lung function and blood gas analysis indexes, adjust MMP-9/TIMP-1 imbalance. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
